Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen, Onyx deal

The companies said Amgen will acquire Onyx for $125 per share in cash, or about $10.4 billion including Onyx's cash. Onyx markets multiple

Read the full 233 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE